Yahoo
    OTC Markets OTCPK - Delayed Quote USD

    Takeda Pharmaceutical Company Limited (TKPHF)

    42.00 +4.03 (+10.61%)
    At close: October 30 at 4:00:00 PM EDT
    Loading Chart for TKPHF
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading

    Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
    PREMIUM
    MT Newswires 1d ago
    What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

    What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
    MarketBeat 2d ago
    Takeda (TAK) Q2 2026 Earnings Call Transcript

    Takeda (TAK) Q2 2026 Earnings Call Transcript
    Motley Fool 2d ago
    Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook

    Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook
    Investing.com 3d ago
    Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

    Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
    Business Wire 3d ago
    2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

    2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
    PR Newswire 6d ago
    Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

    Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
    Business Wire 9d ago
    Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

    Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
    MarketBeat 9d ago
    Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

    Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
    PREMIUM
    MT Newswires 9d ago
    Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors

    Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors
    Exec Edge 11d ago
    Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)

    Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)
    Simply Wall St. 11d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: